



Medicine Supply Notification

MSN/2026/043

Ramipril 1.25mg, 2.5mg, 5mg and 10mg capsules

Tier 2 – medium impact*

Date of issue: 07/09/2026

Link: [Medicines Supply Tool](#)

Summary

- Ramipril 1.25mg, 2.5mg, 5mg and 10mg capsules are in limited supply until the end of October 2026. Note: a Medicine Supply Notification (MSN) and Serious Shortage Protocol (SSP) were issued in April 2026 for the shortage of ramipril 1.25mg capsules and the advice remains live on the [Medicine Supply Tool](#).
- Ramipril 1.25mg, 2.5mg, 5mg and 10mg tablets remain available but cannot support uplift in demand.
- Alternative ACE inhibitors and ARBs remain available; however, routine switching is **not** recommended as usage is significantly lower than that of ramipril, so could risk compromising other supply chains.

Actions Required

Community pharmacy teams and dispensing doctors should:

- ask patients if they have stock available within their homes and delay dispensing if the patient has one month or more worth of supply;
- consider purchasing and dispensing short-dated 5mg stock that is available from wholesalers, ensuring that the patient is notified of the expiry date of the stock;
- conservatively order stock of ramipril capsules in line with usual demand and consider limiting supply to one month to ensure equitable distribution of available stock.

Prescribers should:

- not issue prescriptions for more than one month's supply until the supply issue has resolved;
- limit switching to another ACE inhibitor or an ARB to cases where this is clinically necessary, taking into account the indication for use, treatment history, comorbidities, intolerance to excipients, as well as local guidance/formularies, and ensure the patient is counselled on the dose regimen (see Supporting Information)
- monitor patients who have switched treatment to ensure blood pressure and/or symptoms remain controlled, and the new agent is tolerated, titrating dose as needed, advising them to seek medical advice if they experience dizziness/light-headedness or other adverse effects after switching. Other blood-pressure and cardiovascular medicines should be optimised, if clinically appropriate.

Supporting information

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Clinical Information

Ramipril capsules are licensed for the treatment of hypertension, renal disease, and symptomatic heart failure, and for cardiovascular prevention, including after an acute myocardial infarction.

Refer to CKS table of [ACE inhibitors](#) and [ARBs](#) in hypertension and [ACE inhibitors in heart failure](#) and [ARBs in heart failure](#) for dosing guidance. Summaries of Product Characteristics (SmPCs) should be consulted for full information on licensed indications and dosing regimens.

Links to further information

[BNF – Ramipril](#)

[SmPC – Ramipril](#)

[NICE CKS – Hypertension: ACE inhibitors](#)

[NICE CKS - Hypertension: ARBs](#)

[NICE CKS - Heart failure - chronic: ACE inhibitors](#)

[NICE CKS - Heart failure - chronic: ARBs](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.